Prognostic Value of CA 15.3 Kinetics for Metastatic Breast Cancer

2002 ◽  
Vol 17 (4) ◽  
pp. 231-238 ◽  
Author(s):  
B. De La Lande ◽  
K. Hacene ◽  
J.-L. Floiras ◽  
N. Alatrakchi ◽  
M.-F. Pichon
Keyword(s):  
Breast Cancer ◽  
Lead Time ◽  
Prognostic Value ◽  
Cox Model ◽  
Metastatic Breast ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Ca 15.3 ◽  
Kaplan Meier ◽  
Kinetics Of

Up to 80% of breast cancer patients developing metastases have high levels of CA 15.3. We studied the prognostic implications of CA 15.3 kinetics in 119 patients before and at first metastasis by univariate and multivariate statistics. At first metastasis, CA 15.3 was elevated in 82.4% of patients, with a lead time (median 162 days) in 42.0% of them. Kaplan-Meier analysis showed overall survival (median 1477 days) to be significantly related to estrogen receptor (ER) and progesterone receptor (PgR) status (p=0.0001) and tumor size (p=0.025). The interval between diagnosis and first abnormal CA 15.3 (p=0.0001), the CA 15.3 concentration (p=0.013), and the presence or absence of a lead time (p=0.001) also had prognostic value. ER and PgR status (p=0.0005 and p=0.0103, respectively), metastasis-free interval (p=0.0003), existence of a CA 15.3 lead time (p=0.0028), and days from diagnosis to first abnormal CA 15.3 (p=0.0055) entered in the Cox model. After first metastasis (median survival 573 days), ER and PgR status (p=0.0001 and p=0.0004, respectively), existence of a lead time for CA 15.3 (p=0.0138), and the concentration of first abnormal CA 15.3 (p=0.0145) had individual prognostic value. In the Cox model ER status (p=0.0001), nodal status (p=0.0191), existence of a lead time for CA 15.3 (p=0.0033), days from diagnosis to first abnormal CA 15.3 (p=0.0132), and concentration of first abnormal CA 15.3 (p=0.0320) were found to be independent prognostic variables. Compared to a matched historical control group that was not monitored by CA 15.3 assaying (n=140), the study group had a significantly longer survival after the first metastasis (p=0.0005). In conclusion, the kinetics of CA 15.3 before the first metastasis is of prognostic value. When associated with 18-fluorodeoxyglucose imaging, serial CA 15.3 assays may help to implement early treatment of metastases.

Ca 15.3 as a Tumour Marker in Breast Cancer

1987 ◽  
Vol 2 (3) ◽  
pp. 135-142 ◽  
Author(s):  
Peter Schmidt-Rhode ◽  
Klaus-Dieter Schulz ◽  
Gerhard Sturm ◽  
Anette Raab-Frick ◽  
Helge Prinz
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Tumour Marker ◽  
Primary Treatment ◽  
Breast Diseases ◽  
Breast Cancer Patients ◽  
Ca 15.3 ◽  
Healthy Females

CA 15.3 is an antigenic determinant associated with human mammary carcinomas. Two murine monoclonal antibodies have been raised against the determinants, and an immunoradiometric assay (IRMA-Kit, Centocor, USA) has been developed to determine the antigen levels in plasma of cancer patients. Based on the 99% confidence limit of healthy women, plasma values above 30 U/ml are considered abnormal. Plasma samples from 357 women were examined in the present study. Healthy females (n = 84) ranged below the cut-off level between < 10 and 29 U/ml. Higher values were found in 12.5% of benign breast diseases and in 23.6% of breast cancer patients, including all stages. Depending on the stage of the disease, there were elevated levels in 11% of operable breast cancer patients preoperatively, in 7% of the cases with no evidence of disease after primary treatment and in 63.5% ofpatients with disseminated mammary carcinoma. In metastasized breast cancer the frequency and the degree of abnormal titers were closely related to the extent of the metastatic disease. Follow-up examinations of 63 patients under cytotoxic therapy showed CA 15.3 changes correlating well with the clinical course in up to 90% of the antigen positive cases. The present data indicate that CA 15.3 may be useful in the surveillance of breast cancer patients. However in our study one third of the patients with metastatic breast cancer did not show any increase in CA 15.3 and must be regarded as antigen negative.

The Prognostic Significance of Increasing Marker Levels in Metastatic Breast Cancer Patients with Clinically Complete Remission, Partial Remission or Stable Disease

1998 ◽  
Vol 13 (1) ◽  
pp. 10-15 ◽  
Author(s):  
A. Van Dalen ◽  
V. Barak ◽  
A. Cremaschi ◽  
M. Gion ◽  
R. Molina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Complete Remission ◽  
Cancer Patients ◽  
Stable Disease ◽  
Partial Remission ◽  
Lead Time ◽  
Metastatic Breast ◽  
Breast Cancer Patients

TPS, CA 15-3 and CEA were determined in metastatic breast cancer patients during treatment. After six months of follow-up the patients were divided into four groups according to the UICC criteria for treatment response. Forty-six patients with a more favorable prognosis (complete remission, partial remission or stable disease) were followed for an extended period. In 30 of the 46 patients at least one marker had increased at the end of the six-month period by at least 25% (TPS in 54%, CA 15-3 in 20%, CEA in 20%). All these 30 patients subsequently developed progression. The prognostic sensitivity was 83%, 30% and 30%, respectively, for TPS, CA 15-3 and CEA. The combination of TPS and CA 15-3 showed a sensitivity of 96%. The median lead time was about 8 months for TPS and CA 15-3, but less than 50% of the patients showed a lead time for CA 15-3 as compared to TPS. We conclude that TPS and CA 15-3 determinations are helpful for the prediction of progression during the follow-up of breast cancer patients.

Prognostic value of CA 15.3 kinetics for metastatic breast cancer

2002 ◽  
Vol 17 (4) ◽  
pp. 231-238 ◽  
Author(s):  
B. De La Lande ◽  
K. Hacene ◽  
J.-L. Floiras ◽  
N. Alatrakchi ◽  
M.-F. Pichon
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Prognostic Value ◽  
Metastatic Breast ◽  
Ca 15.3

TPS Monitoring in Metastatic Breast Cancer

1999 ◽  
Vol 14 (1) ◽  
pp. 45-48 ◽  
Author(s):  
A. Van Dalen
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Lead Time ◽  
Metastatic Breast ◽  
Hormonal Treatment ◽  
Breast Cancer Patients ◽  
Favorable Prognosis ◽  
Heterogeneous Nature ◽  
Advanced Stages ◽  
Predict Disease Progression

The management of metastatic breast cancer patients reflects the heterogeneous nature of the disease. While patients may benefit from hormonal treatment, in most cases more toxic chemotherapy is applied in the advanced stages. The pretreatment levels of TPS in patients with metastatic breast cancer are correlated with prognosis. Decreasing TPS levels (>50%) during treatment are indicative of response. The fastest decrease in TPS levels is obtained in patients with a favorable prognosis. Increasing TPS levels (>25%) predict disease progression with a considerable lead time (median 8 months). The clinical impact of these observations is discussed in this paper.

Prognostic value of vitamin-D level in non-metastatic breast cancer patients in Saudi Arabia

The Breast ◽  
2019 ◽  
Vol 44 ◽  
pp. S91
Author(s):  
S. Elsamany ◽  
A. Zeeneldin ◽  
O. Elemam ◽  
S. Elmorsy ◽  
N. Abu Hashish
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Saudi Arabia ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Metastatic Breast ◽  
Breast Cancer Patients

scholarly journals Exosomal miR-1246 is Involved in Tumorigenesis by Targeting THRB in Breast Cancer

2021 ◽  
Author(s):  
Jie Zhu ◽  
Xiaoying Chen ◽  
Fengxiang Xi ◽  
Lei Zhao ◽  
Yichao Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Target Genes ◽  
Metastatic Breast ◽  
Functional Enrichment ◽  
Breast Cancer Patients ◽  
Invasion And Migration ◽  
Kaplan Meier ◽  
Exosomal Mirnas ◽  
And Migration

Abstract Background: Exosomal miRNAs have drawn increasing attention as tumor biomarkers involving in tumorigenesis due to their stability. The aim of this study was to analyze the role of exosomal miR-1246 in breast cancer.Methods: The differentially expressed (DE) miRNAs in exosomes from the serum of breast cancer patients and healthy controls were investigated using RNA-seq. The potential pathogenic target genes and functional enrichment of these miRNAs were explored using bioinformatics. Additionally, the role of miR-1246 in migration, invasion and proliferation were investigated in breast cancer cells. The expression of THRB were detected by QRT-PCR. Kaplan-Meier plotter was used to perform survival analysis.Results: The results showed that the level of exosomal miR-1246 was significantly higher in breast cancer than in the control. MiR-1246 mimic treatment promoted invasion and migration in MDA-MB-231 cells by targeting THRB. Kaplan-Meier survival curves showed that patients with high miR-1246 expression exhibited poor OS compared with patients with low miR-1246 expression, especially those with metastatic breast cancer.Conclusion: Our study provides a better understanding of exosomal miR-1246 in the process of breast cancer. Exosomal miR-1246 could be a potential prognostic biomarker for breast carcinoma.

Sign in / Sign up

Export Citation Format

Share Document